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Introduction
It is well known that interstitial lung disease
(ILD) can be related to a iatrogenic cause (1). The
clinical presentation is variable (dyspnoea, dry
cough) (2) and an inaccurate collection of the pa-
tient’s history can lead to diagnostic and therapeutic
mistakes. An increasing number of medications has
been reported to cause side-effects affecting the res-
piratory system (3-7), but only a little is known
about the lung toxicity of metformin in association
with glibenclamide. In 1986 Klapholz L et al (8) de-
scribed the case of a 56-yr-old woman affected by
type II diabetes treated with glibenclamide (10
mg/day) and metformin (2550 mg/day) with bilater-
al pulmonary infiltrates at a chest X-ray and diffuse
papulous skin lesions, histologically proven as leuco-
cytoclastic vasculitis. The withdrawal of the oral hy-
poglycemic therapy, which was shifted to insulin
therapy, and treating the patient with prednisone
(0.5 mg/kg/day) led to a rapid resolution of the radi-
ologic findings along with the improvement of the
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skin lesions in 10 days. Two weeks after the inter-
ruption of the corticosteroid therapy, metformin was
reintroduced and, 2 days later, the patient showed a
relapse of the dermatologic pathology. The Authors
concluded that metformin, rather than gliben-
clamide, had an etiologic role in causing both the cu-
taneous lesions and the lung findings.
Case report
A 78-yr-old Caucasian non smoker woman was
admitted to our Division referring a 3-month history
of mild dyspnoea at rest, asthenia and fever. Her med-
ical history was remarkable for the following condi-
tions: arterial systemic hypertension, treated with
carvedilol (12.5 mg/day) for 5 years, in combination
with furosemide (50 mg/day) and ramipril (10
mg/day) for 4 years; ischemic heart disease, i.e. an
acute heart attack episode occurred 4 years before,
treated first with percutaneous transluminal coronary
angioplasty (PTCA) and then, 7 months later, with
aorto-coronary by-pass; chronic atrial fibrillation on
oral anticoagulation treatment with warfarin for 3
years. Metabolic disorders included hypercholes-
terolemia, treated with atorvastatin (20 mg/day) for 3
years, and type II diabetes on therapy with an associa-
tion of oral hypoglycemic drugs, whose dosage was in-
creased in the last 3 months due to the poor control of
glycemia levels (metformin from 1200 mg/day to 2000
mg/day and glibenclamide from 7.5 mg/day to 12.5
mg/day).The patient was a housewife with no domes-
tic animals. Further exposure to environmental agents
likely causing respiratory diseases was excluded after a
careful interview.Allergy was ruled out as well.On ad-
mission, the patient was awake and alert, suffering
from mild dyspnoea at rest. No further clinically sig-
nificant signs were appreciated. Body temperature was
36.8°C. Atrial fibrillation was present with a heart rate
estimated between 70-80 beats a minute, while blood
pression was normal. The physical examination (i.e.,
auscultation) of the thorax revealed the presence of in-
spiratory bilateral crackles in the lower lung fields.
Blood gases analysis was performed while the patient
was breathing ambient air at rest.To date, arterial oxy-
gen partial pressure (pO2) was of 52.7 mmHg, carbon
monoxide pressure (pCO2) was of 37.2 mmHg with a
PH of 7.45. Routine haematological and biochemical
parameters were within the normal range. A mild ane-
mia was instead appreciated along with increased
serum levels of glucose and glycosylated haemoglobin
(HbA1c) (12.1 %, normal range: 3.5-6 %). Searching
for commonly tested auto-antibodies (Abs) (including
rheumatoid factor, antinuclear, anti-citrullinated pro-
teins, anti-DNA, anti-smooth muscle, anti-extractable
nuclear antigens, anti-neutrophil cytoplasmic Abs)
was negative. Serology for common respiratory viruses
and bacterial intracellular pathogens (including RSV,
CMV, EBV, Influenza viruses, Parvovirus B19,
Chlamydia pneumoniae and Mycoplasma pneumoni-
ae) was also negative. Pulmonary function testing
(PFT) revealed a mild restrictive ventilatory pattern
with a still preserved total lung capacity (TLC 4.16 L,
81.5 % of predicted). To date, the absolute value of
forced vital capacity (FVC) was 1.67 L (63.5 % of pre-
dicted) as forced espiratory volume/1’ sec (FEV1)
(1.67 L, 80.5 % of predicted) with an absolute Tiffe-
neau index of 100 %. The Hb-corrected single breath
lung diffusion capacity of carbon monoxide (DLCOsb)
was moderately compromised (3.40 mmol/min/KPa;
49.7% of predicted). Standard chest X-ray showed bi-
lateral infiltrates in the lower lung zones. High resolu-
tion computed tomography (HRCT) of the thorax re-
vealed extensive and patchy ground glass opacities
throughout the lung vertical axis with higher preva-
lence in the lower fields (cranio-caudal gradient).
These findings were suggestive of alveolar involve-
ment. Areas of normal pulmonary parenchyma were
appreciated between ground glass opacities (Figure
1.A). Microbiological examination of three induced
sputum samples collected on consecutive days was
negative. Searching for malignant cells was also nega-
tive. Fiber-bronchoscopy and broncho-alveolar lavage
(BAL) collection for further cytology, microbiology
and immunology studies were not performed as the
patient refused the exam.While the patient was under
investigation, oral hypoglycemic therapy was suspend-
ed and insulin therapy was initiated to allow a better
control of diabetes. The clinical conditions of the pa-
tient started to improve after the first 48 hours of in-
sulin treatment. Repeated blood gas analysis showed
an increase of pO2 to 79.4 mmHg. The patient was
discharged after 12 days of hospitalization with no in-
dication of additional therapies and with a planned
control visit at 3 months. In that occasion, the patient
was no more symptomatic, chest physical examination
was unremarkable and PFT were within the normal
range, with Hb-corrected DLCOsb estimated at 6.13
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mmol/min/KPa (90.1% of predicted). Routine haema-
tological/biochemical parameters and blood gases
analysis were also within the normal range. HRCT
scan of the thorax showed a significant improvement
with the almost complete resolution of the aforemen-
tioned alterations (Figure 1.B).
Discussion
Adverse effects of drugs on the respiratory system
have become an important issue in pulmonary practice.
Indeed, the list of medications causing ILD has ex-
panded markedly over the past 30 years (1-7). Howev-
er, to our knowledge very little is known about the
causal relationship between oral hypoglycemic drugs
and lung toxicity. Usually, drug-induced ILD develops
after the patient has used the drug for a long period and
symptoms improve once the drug is withdrawn. Cases
of ILDhave also been described after weeks or years af-
ter treatment termination.
Herein we report the case of an elderly diabetic
woman who developed progressive dyspnoea, fever and
asthenia soon after increasing the dosage of met-
formin/glibenclamide due to the poor glycemia control.
As symptoms were persisting over a 3-month period
the patient was referred to our Division where thorax
imaging revealed the presence of bilateral ground glass
opacities in the lower lung fields. The clinical condi-
tions of the patient improved significantly very shortly
(2 days) after starting insulin therapy in spite of oral hy-
poglycemic drugs. Such an observation led us to hy-
pothesize the existence of a causal link between the
dose change of metformin/glibenclamide and the oc-
currence of lung disease. After excluding other known
etiologies, the significant improvement in PFT along
with the almost complete resolution of the radiologic
findings in the absence of any additional therapeutic ef-
fort at 3 months further supported this belief.
A similar case was previously reported by
Klapholz L et al. (8). As in our patient, clinical im-
provement was obtained after drug withdrawing but it
was observed over a longer period (10 days). In addi-
tion, the use of corticosteroid therapy was needed. Fi-
nally, lung disease was not isolated as skin involvement
was also present. As disease relapse occurred after met-
formin re-introduction the Authors definitely identi-
fied metformin as the causative agent.Unfortunately, in
our case, in the absence of further literature evidence for
comparison, it is quite difficult to argue to which extent
the causative role has to be attributed to metformin or
to glibenclamide.
Diabetes treatments have been related with ei-
ther an increased or reduced risk of cancer. In a re-
cent meta-analysis by Franciosi M et al. the use of
metformin has not been associated with the risk of
cancer and cancer-related mortality in diabetic pa-
tients (9). Conversely, as metformin also displays sig-
nificant growth inhibitory and pro-apoptotic effects,
its usage, alone or in combination with chemothera-
peutic drugs, has been proposed for treatment pur-
poses in several cancer models, including lung cancer
(10). However, as epidemiological data have shown
contrasting results in this issue, deciphering targeted
molecular pathways is still under investigation.
Fig.1.Thorax HRCT performed on hospital admission revealed the
presence of areas of heterogeneous and extensive increase in lung
density, i.e.,ground glass opacities (arrows), through the vertical axis
with higher prevalence in the lower lobes suggesting a fluid alveolar
involvement (A).Amarked improvement leading to the almost com-
plete resolution of the imaging findings with no distortion of the in-
terstitial architecture was appreciated after three months of stopping
oral anti-diabetic therapy (B).
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Conclusions
To our knowledge, this is the second literature
report of a case of ILD related to treatment with
high doses of metformin/glibenclamide in a poorly
controlled diabetic woman.
Clinicians should always be aware about the
likely link occurring between lung pathology and
drugs in the diagnostic work-up of ILD.
While liver and kidney drug-related side effects
are routinely screened in clinical practice, less atten-
tion is paid to lung toxicity with under-diagnosis
consequences, especially in elderly patients.
Informed consent
Written informed consent was obtained from
the patient for publication of this report and of any
accompanying images.
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